Sheffield Children's NHS Foundation Trust | Sheffield Children's Hospital - Clinical Research Facility

Research site

(Unclaimed)

Location

Sheffield Children's Hospital, Sheffield, Sheffield, England

Site insights

Top conditions

Top treatments

BMN 111

Posoleucel

Gemtuzumab

Glucose

Fesoterodine

UX007

IV tetracosactide

daunorubicin

Cyclophosphamide

PF-04965842

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 47 total trials

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a hei...

Active, not recruiting

Achondroplasia

Biological: vosoritide

A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex (EpiCom)

The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1...

Enrolling

Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

Drug: Cannabidiol Oral Solution [Epidiolex]

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 i...

Active, not recruiting

Achondroplasia

Drug: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia

Active, not recruiting

Achondroplasia

Drug: BMN 111

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

The main purpose of this study is :1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can b...

Enrolling

Acute Myeloid Leukaemia

Drug: Cyclophosphamide

Drug: Mitoxantrone

Study to Assess Dose, Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta (Orbit)

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs...

Active, not recruiting

Osteogenesis Imperfecta

Other: Placebo

Biological: Setrusumab

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg